FDA Clears Victoza, But Warnings And More Studies Pose Hurdles
By
The Pink Sheet / Email the Author / “The Pink Sheet” Feb. 1, 2010, Vol. 72, No. 005
New Products / Word Count: 1080 / Article # 00720050008
Executive Summary
That FDA's approval of Novo Nordisk's Victoza (liraglutide) uses its full cadre of FDA Amendments Act-granted drug safety controls - a Risk Evaluation and Mitigation Strategy and mandatory post-marketing requirements - is not surprising, given the concern about a potential cancer risk. But it is a disappointment to investors
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.